MENUNews Archive
Date: 10/07/2013
About a quarter of women experience moderate to severe pain for many years after their treatment ends. In many cases, it's a type of pain that is challenging to treat, with few or no effective options.
Date: 10/03/2013
A microfluidic chip developed at the University of Michigan is among the best at capturing elusive circulating tumor cells from blood -- and it can support the cells' growth for further analysis.
Date: 09/26/2013
Michigan Medicine has begun offering a new urine test called Mi-Prostate Score to improve on PSA screening for prostate cancer. The test incorporates three specific markers that could indicate cancer and studies have shown that the combination is far more accurate than PSA alone.
Date: 09/23/2013
Recent studies have suggested that an informed patient will be less likely to choose a more-extensive treatment than what the doctor recommends but a recent study by University of Michigan Rogel Cancer Cetner researchers have found that's not necessarily the case.
Date: 09/06/2013
Written by Kara Gavin; contact via email or at 734-764-2220.
Date: 09/06/2013
A new study from researchers at the University of Michigan Rogel Cancer Center found that these cells, called myeloid derived suppressor cells, provide a niche where the cancer stem cells survive.
Date: 08/16/2013
Despite taking a tailored risk assessment tool that factors in family history and personal habits, nearly 20 percent of women did not believe their breast cancer risk, according to a new study from the University of Michigan Rogel Cancer Center.
Date: 08/16/2013
Xofigo, a newly approved treatment for advanced prostate cancer, delivers a powerful punch of radiation directly to tumor cells that have invaded the bone.
Date: 08/03/2013
Results from research at the University of Michigan indicate that if mice have healthy gastrointestinal tract, the chances of surviving high doses of chemotherapy increase.